Overview of nebuliser treatment

M F Muers

Historical perspective

The word “nebuliser (from the Latin “nebula”, mist) was first used in 1872 and was defined in 1874 as “an instrument for converting a liquid into a fine spray, especially for medical purposes”.¹ The idea of producing a vapour or aerosol for the treatment of lung disease was by no means new even then since smoke and steam had been used in this way for centuries. Inhalation devices depending on mouth suction to draw air through a liquid were produced for essential oil treatment in the 18th century and similar devices were employed when antiseptic inhalations were advocated for the treatment of tuberculosis.² Although early inhalation devices depended on steam (fig 1), mechanical pumps to generate the gas flow for nebulisation were made in the 19th century and these were eventually supplanted by electrical compressors in the 1930s. Early nebuliser chambers were essentially simple atomisers – like the glass and hand bulb atomisers first introduced for asthma treatment in the 1930s (fig 2). These generated an aerosol with a wide range of particle sizes and much of the output was non-respirable. Modern jet nebuliser chambers use a combination of high gas flow, precise Venturi orifices, and baffles to restrict the size of the particles emitted more closely to those of respirable size (1–5 µm diameter) and thereby increase lung deposition and treatment efficacy. These designs depend upon the availability of precision engineering, originally of ebonite and perspex – for example, the Wright nebuliser of the 1950s (fig 3) – and now injection moulded plastics. By contrast, ultrasonic nebulisers which rely on high frequency sound waves induced by the vibration of a piezoelectric crys-

tal were not introduced until the 1960s.³ More recently, equipment development has focused on breath assisted chambers which generate an even higher percentage of respirable particles and can facilitate aerosol treatment with a wide variety of drugs, drug suspensions, and solutions with different physicochemical properties (fig 4). Progress towards the matching of specific equipment to particular types of drug delivery is likely to continue. Future treatment may well include a greater use of the products of recombinant gene technology – for example, rhDNase, α_1 -antitrypsin – as well as specific anti-inflammatory mediator drugs for both interstitial lung disease and obstructive air flow disease, and possibly cytokines and cell surface receptors for the treatment of endobronchial neoplasia.

Despite this expanding range of nebuliser therapies, there is a need for physicians to recognise that, for the foreseeable future, the principal use worldwide will be for bronchodilatation. By extrapolation from a regional study⁵ it is possible to estimate that there are currently about 40 000 compressors in use for adult domiciliary treatment in the UK with an associated drug cost of approximately £40 million annually. A recent audit of a large Scottish teaching hospital revealed an annual use of 32 000 daily doses of nebulised bronchodilators.⁶ Elsewhere in Europe usage may be even higher. Brandli⁷ has reported a figure of 215 nebulisers per 10⁵ population in Switzerland compared with 70 per 10⁵ in the UK survey. Nevertheless, as so often happens with physical treatments in medicine, widespread use has preceded much needed, more fundamental work in optimising drug delivery. The reason for this is that modern compressors and nebulisers are efficient, large doses of drugs are used, and they are especially effective for emergency treatment. It is clear from Appendix 5 on pp S23–24 of the guidelines that much research still needs to be done to optimise even straightforward nebuliser treatment.

Nebulisers in clinical medicine

Table 1 is a summary of the present uses of nebulisers in clinical medicine. Although the articles in this supplement concentrate on the use of nebulisers for treatment, it must be noted that, in parallel, much work has been done on their use – usually in a more precise way – in generating respirable aerosols for diagnostic purposes and for physiological measurement and basic lung research. For example, the use of radioactively labelled DTPA aerosols for the measurement of alveolar epithelial permeability depends critically on using a system able to generate large numbers of particles with a mass

Killingbeck Hospital,
York Road, Leeds
LS14 6UQ, UK
M F Muers

Correspondence to:
Dr M F Muers.

Figure 1 Example of 19th century nebuliser equipment. Seeger's steam nebuliser from Geo. Tiemann and Co's Surgical Instrument Catalogue, New York, 1876.

Figure 2A and B The DeVilbiss No 40 glass nebuliser. Reproduced with permission from Mercer.³

Figure 3A and B The Wright perspex nebuliser. 1 = cap; 2 = inlet connection; 3 = outlet connection; 4 = jet; 5 = knurled nozzle; 6 = baffle plate; 7 = flexible feeding tube. Reproduced with permission from Wright.⁴

Figure 4 Examples of modern nebuliser chambers. (A) Simple jet nebulisers: Unimed; Lifecare; Hudson Up-draft II. (B) Breath assisted nebulisers: Ventstream (left); Sidestream (right) (Medic-Aid).

Table 1 Uses of nebulisers in clinical medicine

		Reference
Diagnosis:		
Lung physiology		
Ventilation	^{99m} TTPA <3 µm MMAD	8
Mucociliary clearance	Albumen microspheres >5 µm MMAD	9
Epithelial permeability	^{99m} TTPA 0.5–3 µm MMAD	10
Airway reactivity	Histamine, methacholine	11
Airway reversibility		
Cough threshold	Citric acid, capsaicin	
Lung cell sampling		
Sputum induction	3N NaCl ultrasonic	12
Treatment:		
Airway obstruction	Bronchodilators, steroids	
Infection	Antimicrobials	
Abnormal secretions	Mucolytics (saline, acetylcysteine, rhDNase)	
Cough	Local anaesthetics	
Breathlessness	Opiates	

MMAD = mass median aerodynamic diameter.

median aerodynamic diameter (MMAD) of 0.5–2 µm.¹⁰ By contrast, delivery of therapeutic aerosols is often far less precise. “Shell” analysis of the distribution of inhaled particles generated by different commonly used nebuliser chambers has shown elegantly how drug distribution to different generations of bronchi can vary enormously.¹³

INDICATIONS FOR TREATMENT WITH NEBULISERS

The absolute indications for treatment with nebulisers are relatively few (table 2). They have to be used (1) where the drug is not available as a hand held inhaler, (2) where drug delivery to the alveoli is needed (for example, pentamidine for the prophylaxis or treatment of pneumocystis pneumonia), and (3) when a patient is too ill or is incapable of using a hand held inhaler.

All other indications for nebuliser treatment are relative. Dose escalation can be achieved with multiple actuations of a hand held inhaler, even in emergency treatment,^{14 15} although patients may prefer the relative ease of a nebuliser to taking 12–50 actuations of a hand held inhaler for an equivalent drug dose. Thus, although in theory hand held inhalers may be substituted for nebulisers in acute treatment (and this is increasingly so in paediatric practice), most adult patients and emergency services will continue to prefer nebulisers for their convenience and the reassurance that, even with unrestricted tidal volume breathing, the drug is being inhaled. Otherwise it remains a reasonable principle that, where drugs are available both in hand held inhalers and in nebuliser solutions, compliance with treatment, technique with hand held inhalers, and the benefit from them should be carefully checked before regular nebuliser treatment with all its complexity and expense is advised.

EFFICACY

If the purpose of nebuliser treatment is to obtain a response from the interaction between drug molecules and lung cell receptors, it follows that the most straightforward way of assessing efficacy is by physiological measurement.

The treatment of acute airflow obstruction may be measured by simple physiological responses with a clear correlation between these and symptom relief. Nevertheless, criteria for establishing what is an unequivocal bronchodilator response have evolved and are not yet well established (table 3). The assessment of response in patients with chronic airflow obstruction when airway disease is much less reversible is quite different. There may be poor correlation between measurements of exercise capacity, validated symptom scores, and measurements of bronchodilatation.²⁶ Furthermore, there is no well validated criterion as to what is an unequivocal physiological response in terms of peak flow changes (table 3).^{23 24} Increasing attention is being given to the use of other measures such as the six minute walk,

Table 2 General indications for treatment with nebulisers

Absolute indications:
(1) Too sick or incapable of managing hand held inhalers.
(2) Drug not available in hand held inhalers.
(3) Need to target treatment to particular generations of bronchi or the alveoli.
Relative indications:
(1) Need for a large drug dose.
(2) Patient preference.
(3) Practical convenience.

Table 3 Criteria for identifying bronchodilator responses

	Reference
Repeat measurements on one day	
FEV ₁ >15% of baseline	16
FEV ₁ >9% of baseline	17
FEV ₁ and FVC >200 ml	18
FEV ₁ and FVC >12% of baseline and >200 ml	19
FEV ₁ and FVC >12% of predicted and >200 ml	20
PEF >60 ml	21
Repeat PEF measurements over several days	
Corticosteroid >20% baseline, mean 7 days	22
trials >15% baseline, mean 7 days	23
Nebuliser >15% baseline, mean 7 days	24
assessments	
Reproducibility (PEF)	
Best two measures within 20 l/min	25

FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; PEF = peak expiratory flow.

symptom relief, and quality of life questionnaires²⁶ as more valid criteria to judge the efficacy of treatment in chronic disease. The same caveats apply to the use of nebulisers for antimicrobials and palliative drugs where, apart from a few studies in cystic fibrosis, well conducted trials of treatment are sparse and end points for judging benefit are not precise (table 4). As discussed in the following papers, this is an area where emphasis on major research is long overdue.

In this context it is perhaps salutary to note that these unmet needs have been recognised since 1929 when a London general practitioner, Dr P W L Camps, wrote *A note on the inhalation treatment of asthma!*²⁷

Equipment

The in vitro measurement of the output characteristics of nebuliser systems is an important corollary to the measurement of clinical efficacy. The development of national (UK, BS 5724) and international (European, IEC 601–1) standards should act as a stimulus in this direction. Examples of how establishing standard methodologies could affect this field are the recent recommendation that a multi-stage impinger rather than a two stage device should be used to measure drug particle size distribution,²⁸ the increasing realisation that direct drug output estimates rather than gravimetric methods are superior for assessing nebuliser chamber performance,²⁹ and the recognition that quality control in the manufacture of chambers is important to ensure that there is a low unit to unit variation in output characteristics.³⁰ Consideration probably ought to be given to the suggestion that there should

be reference laboratories using standardised methods and able to publish reliable and comparable data on the function of compressor/nebuliser combinations. At present much of this information is difficult to obtain and comes from several disparate sources. Direct comparisons between equipment are relatively sparse, and are themselves difficult to compare because of different methods and criteria for assessment.^{29 31}

Reviews of nebuliser use in clinical practice

Few reviews or audits of nebuliser use in institutions or communities have been published but even this small literature has shown a disturbing picture. Caldwell *et al*⁶ found that more than 50% of treatments in a large Scottish teaching hospital were incorrectly prescribed (inefficient gas flows, small fill volumes, etc) while more than 20% of prescriptions used water rather than saline to dilute bronchodilators and 30% of equipment was not cleaned daily. Similarly, only 7% of nebuliser prescriptions reviewed on five medical wards of an English teaching hospital were correct.³² The circulation of fairly simple directions can change technique abruptly, and both studies reported improvements after such procedures. However, only 30% of prescriptions in the English study were subsequently correct and this emphasises the point that patient and staff education has to be a continuing process and a single directive is not adequate.

Similarly, both national and international comparisons have shown an unreasonable variation in nebuliser treatment use and, by implication, unreasonable differences in clinical practice. In a UK regional survey,⁵ for instance, compressor use for domiciliary treatment varied between districts from four to 213 per 10⁵ population. The European 1992 international asthma survey³³ showed a similar variation in reports by physicians on their use of nebulisers for airway disease (fig 5). Such variations may represent, in part, varying access by patients and doctors to funding, but almost certainly they also reflect inconsistencies in the interpretation of present evidence about the suitability of nebuliser treatment. In contrast, in situations where there is a clearly restricted and detailed clinical indication and care has been taken to specify the details of nebuliser technique, they are likely to be approached in a much more uniform way. Examples are

Table 4 Measuring the efficacy of nebuliser treatment

Drug	Problem	Objective	Usual measurements	Agreed criteria for response
Bronchodilators	Acute airway obstruction	Rapid bronchodilatation	PEF FEV ₁	+
Bronchodilators	Chronic air flow limitation	↓ disability	PEF, ? exercise test, ? validated questionnaires	±
Steroids	Chronic air flow limitation	Bronchodilatation, ↓ oral dose	PEF, oral dose	±
Antimicrobials	Chronic infection	Fewer exacerbations, less secretions	?	—
Mucolytics	Abnormal secretions	Better physiology, ? patient comfort	?	—
Local anaesthetics	Cough	↓ frequency	Cough count	—
Opiates	Breathlessness	Palliation	VAS or questionnaire	±

PEF = peak expiratory flow; FEV₁ = forced expiratory volume in one second; VAS = visual analogue scale.

Figure 5 Percentage of pulmonologists from 19 European countries using nebulisation often or always for (A) β agonists in adults; (B) anticholinergics in adults; (C) cromoglycate in children; (D) steroids in children. Reproduced with permission from Verniere.³⁵

the use of particular nebuliser chambers for pentamidine and the US Food and Drug Administration (FDA) recommendation of the small particle aerosol generator (SPAG) to nebulise ribavirin.

There has been little concerted effort, either national or international, to pool experience, examine details of practice, and establish a consensus of best clinical practice. A 1991 US aerosol consensus statement³⁴ has general recommendations regarding hand held inhalers and nebuliser use but details were restricted to recommended precautions by health care workers for the administration of pentamidine and ribavirin. A Dutch group has recently produced specifications for nebuliser equipment³⁵ and these have been mirrored by the published UK and European equipment standards. However, good nebuliser treatment requires more than equipment specifications.³⁶ Details of indications, drugs, timing, etc are also all relevant. To improve the situation more collaboration is needed between health service administrators, the medical profession, and the pharmaceutical and equipment manufacturing industries. National and international respiratory societies are in a good position to take

the lead in establishing such ventures and the benefits both to health services and to patient care should be large.

Conclusions

The purpose of this document is (1) to gather together authoritative reviews of the evidence for nebuliser treatment in different clinical situations; (2) to provide clinicians with accessible information on the scientific basis of nebuliser treatment and the factors to be considered in using and choosing equipment and running a domiciliary service; (3) to present a summary of recommendations – as guidelines – on treatment with nebulisers for physicians, together with a short precis for general practitioners and example information sheets for patients and nursing staff; and (4) to highlight the particular areas where future research on nebuliser treatment can usefully be directed. It is hoped that improvements in the provision of nebuliser treatment will ensue and that patients will correspondingly benefit.

1 Shorter Oxford English Dictionary. 3rd edn. Oxford: Clarendon Press, 1950.

2 Mathu DL. *Pulmonary tuberculosis. Its aetiology and treatment.* London: Balliere Tindall and Fox, 1922: 266–9.

3 Mercer TT. Production of therapeutic aerosols: principles and techniques. *Chest* 1981;**80**:S813–7.

4 Wright BM. A new nebuliser. *Lancet* 1958;ii:24.

5 Hosker HSR, Teale C, Greenstone MA, Muers MF. Assessment and provision of home nebulizers for chronic obstructive disease (COPD) in the Yorkshire region of the UK. *Respir Med* 1994;**89**:47–52.

6 Caldwell NA, Milroy R, McCabe J, Banham SW, Moran F. An audit of nebulization technique in a major teaching hospital: scope for improvement. *Pharm J* 1991;**247**:706–8.

7 Brandli G. Maintenance and servicing of nebulizers. *Eur Respir Rev* 1994;**4**(Suppl 18):102–3.

8 Alderson PO, Bielo DR, Gottshalk A, Hoffer PB, Kroop SA, Lee ME, *et al.* Tc-99m DTPA aerosols and radioactive gases compared as adjuncts to perfusion scintigraphy in patients with suspected pulmonary embolism. *Radiology* 1984;**153**:515–21.

9 Pavia D, Sutton PP, Agnew JE, Lopez-Vidriero MT, Newman SP, Clarke SW. Measurement of bronchial mucociliary clearance. *Eur J Respir Dis* 1983;**127**(Suppl):41–56.

10 Barrowcliffe MP, Jones JG. Solute permeability of the alveolar capillary barrier. *Thorax* 1987;**42**:1–10.

11 European Respiratory Society. Airway responsiveness: standardised challenge testing with pharmacological physical and sensitising stimuli in adults. Working Party Report. *Eur Respir J* 1993;**6**(Suppl 16):53–83.

12 Bigby TD, Margolskee D, Curtis JL, Michael PF, Sheppard D, Hadley WK, *et al.* The usefulness of induced sputum in the diagnosis of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome. *Am Rev Respir Dis* 1986;**133**:515–8.

13 Conway JH, Halson P, Moore E, Hashish A, Bailey AG, Nassim M, *et al.* Multi-modality imaging: the use of single photon emission computed tomography and magnetic resonance imaging to assess regional intra-pulmonary deposition of nebulized aerosols. *J Aerosol Med* 1995;**8**:341–56.

14 Morgan MDL, Singh BV, Frame MH, Williams SJ. Terbutaline aerosol given through pear spacer in acute severe asthma. *BMJ* 1982;**285**:849–50.

15 Freeland S, Van Asperen N. Nebuhaler vs nebulizer in children with acute asthma. *BMJ* 1984;**288**:1873–4.

16 American Thoracic Society. Snowbird workshop on standardisation of spirometry. *Am Rev Respir Dis* 1979;**119**:831–8.

17 Dales RE, Spitzer WO, Tousignant P, Schecter M, Suissa S. Clinical interpretation of airway response to a bronchodilator: epidemiologic considerations. *Am Rev Respir Dis* 1988;**138**:317–20.

18 Tweedale PM, Alexander F, McHardy GJR. Short term variability in FEV₁ and bronchodilator responsiveness in patients with obstructive ventilatory defects. *Thorax* 1987;**42**:487–90.

19 American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. *Am Rev Respir Dis* 1991;**144**:1202–18.

20 European Respiratory Society. Standardised lung function testing. *Eur Respir J* 1993;**6**(Suppl 16):5–40.

21 Dekker FW, Schrier AC, Sterk PJ, Dijkman JH. Validity of peak expiratory flow measurement in assessing reversibility of air flow obstruction. *Thorax* 1992;**47**:162–6.

22 Mitchell DM, Gildeh P, Rehahn M, Diamond AH, Collins JV. Effect of prednisolone in chronic airflow limitation. *Lancet* 1984;ii:193–6.

23 Wardman AG. The diagnosis and treatment of adults with obstructive airways disease in general practice. MD thesis, University of Edinburgh, 1985.

24 Goldman JM, Teale C, Muers MF. Simplifying the assessment of patients with chronic airflow limitation for home nebulizer therapy. *Respir Med* 1992;**86**:33–8.

25 Weir DC, Gove RI, Robertson AS, Sherwood Burge P. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. *Thorax* 1990;**45**:112–7.

26 Jones PW. Quality of life measurement for patients with diseases of the airways. *Thorax* 1992;**47**:676–82.

27 Camps PWL. A note on the inhalation treatment of asthma. *Guy's Hosp Rep* 1929;**79**:496–8.

28 Rogers DR, Ganderton D, eds. British Association for Lung Research: workshop report. Determining equivalence of inhaled medications. *Respir Med* 1994;**89**:253–61.

29 Dennis JH, Stenton SC, Beach JR, Avery AJ, Walters EH, Hendrick DJ. Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. *Thorax* 1990;**45**:728–32.

30 Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers: how reliable are they? *Chest* 1992;**101**:316–9.

31 Smith EC, Denyer J, Kendrick AH. Comparison of 23 nebulizer/compressor combinations for domiciliary use. *Eur Respir J* 1995;**8**:1214–21.

32 Craig IR, Riley MR, Cooke NJ. Prescribing of nebulized bronchodilators – can we change bad habits? *Respir Med* 1989;**83**:333–4.

33 Vermiere P. European trends in inhalation therapy. *Eur Respir Rev* 1994;**4**(Suppl 18):89–91.

34 American Respiratory Care Foundation and the American Association for Respiratory Care. Aerosol consensus statement. *Chest* 1991;**100**:1106–9.

35 *Quality guidelines: nebulizers in home health care.* TNO Prevention and Health, Division of Technology and Health Care, Liddem, The Netherlands, 1994.

36 Muers MF. The rational use of nebulizers in clinical practice. *Eur Respir Rev* 1997 (in press).